Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Madison Clinton

Physician Assistant Rockville, MD Physician Assistant

NPI 1093420408 CMS profile 11435155

9601 Blackwell Rd 350, Rockville, MD 20850

Open in the dashboard

General payments

$6,069

246 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Madison Clinton of Rockville, MD is reported in the CMS Open Payments database as having received $6,069 across 246 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,348 96
2024 General $2,290 90
2023 General $1,431 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madison Clinton
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Madison Clinton were reported at $2,348. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Madison Clinton Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $1,431 $167 $52–$557 $160
2024 $2,290 $178 $55–$600 $164
2025 $2,348 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $943 38 payments
  2. Regeneron Healthcare Solutions, Inc. $800 30 payments
  3. GlaxoSmithKline, LLC. $769 31 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $644 25 payments
  5. Novartis Pharmaceuticals Corporation $448 21 payments
  6. Grifols USA, LLC $388 16 payments
  7. Amgen Inc. $323 15 payments
  8. ARS Pharmaceuticals Operations, Inc. $278 11 payments
  9. Genentech USA, Inc. $192 9 payments
  10. ALK-Abello, Inc $172 7 payments
  11. Other $1,110 43 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $5,995 244 payments
  2. Education $52 1 payment
  3. Consulting Fee $22 1 payment
Products named General payments · program years 2023–2025
  1. DUPIXENT $575 22 payments
  2. AIRSUPRA $551 18 payments
  3. NUCALA $501 19 payments
  4. FASENRA $374 15 payments
  5. Prolastin-C Liquid $304 12 payments
  6. TAKHZYRO $300 12 payments
  7. TEZSPIRE $298 14 payments
  8. CUVITRU $293 11 payments
  9. NEFFY $278 11 payments
  10. TRELEGY ELLIPTA $267 12 payments
  11. Other $2,962 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$10,780

Medicare's payments for the services billed

Medicare patients

32

Average age 74

Services billed

864

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 53%
High blood pressure 50%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $411
$411 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $213
  • Genentech USA, Inc. $124
$337 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $282
$282 — —
TEZSPIRE
  • Amgen Inc. $97
  • AstraZeneca Pharmaceuticals LP $57
$153 — —
TAKHZYRO
  • Takeda Pharmaceuticals U.S.A., Inc. $144
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

246 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record